An injectable elastin-based gene delivery platform for dose-dependent modulation of angiogenesis and inflammation for critical limb ischemia

Dash, Biraja C.; Thomas, Dilip; Monaghan, Michael G.; Carroll, Oliver; Chen, Xizhe; Woodhouse, Kimberly A.; O’Brien, Timothy; Pandit, Abhay

doi:10.1016/j.biomaterials.2015.06.037

Cited by 53 publications

(29 citation statements)

References 47 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DNA release rate corresponded to the degradation rate of the polymer, with the scaffold degrading first. Overall, this study [83] demonstrated controlled release, with this particular treatment leading to a reduction in inflammation and an increase in blood vessel density.…”

Section: Proteins and Peptide Nanomaterials For Gene Deliverymentioning

confidence: 83%

“…The fourth amino acid choice in the repeat unit (X) allows the ELPs to have a tunable T t [82]. Dash et al [83] designed a dual ELP-based delivery system to deliver two different gene payloads. This ELP-injectable system was composed of an ELP gel scaffold and ELP hollow spheres that had been used for gene delivery previously [84].…”

Section: Proteins and Peptide Nanomaterials For Gene Deliverymentioning

confidence: 99%

“…This ELP-injectable system was composed of an ELP gel scaffold and ELP hollow spheres that had been used for gene delivery previously [84]. This dual system allowed them to deliver two different plasmids, one encoding endothethial nitric oxide synthase (eNOS) in the ELP hollow spheres, and a second one encoding interleukin-10 (IL-10) in the ELP gel scaffold, to human umbilical vein endothelial cells (HUVEC) cells, to modulate angiogenesis and inflammation to treat critical limb ischemia [83]. The DNA release rate corresponded to the degradation rate of the polymer, with the scaffold degrading first.…”

Section: Proteins and Peptide Nanomaterials For Gene Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Nanomaterials for Gene Delivery—A Review

2017

View full text Add to dashboard Cite

With the rapid development of nanotechnology in the recent decade, novel DNA and RNA delivery systems for gene therapy have become available that can be used instead of viral vectors. These non-viral vectors can be made of a variety of materials, including inorganic nanoparticles, carbon nanotubes, liposomes, protein and peptide-based nanoparticles, as well as nanoscale polymeric materials. They have as advantages over viral vectors a decreased immune response, and additionally offer flexibility in design, allowing them to be functionalized and targeted to specific sites in a biological system with low cytotoxicity. The focus of this review is to provide an overview of novel nanotechnology-based methods to deliver DNA and small interfering RNAs into biological systems.

show abstract

Section: Proteins and Peptide Nanomaterials For Gene Deliverymentioning

confidence: 83%

Section: Proteins and Peptide Nanomaterials For Gene Deliverymentioning

confidence: 99%

Section: Proteins and Peptide Nanomaterials For Gene Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Nanomaterials for Gene Delivery—A Review

2017

View full text Add to dashboard Cite

show abstract

“…One study focused on the treatment of critical limb ischemia [168] using an injectable system comprised of ELP hollow spheres within an in situ -forming ELP gel scaffold to deliver plasmid eNOS and IL-10. H&E stains of C57BL/6 mouse sections were performed following an in vivo subcutaneous study to determine blood vessel density (e.g.…”

Section: Applicationsmentioning

confidence: 99%

Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines

Despanie

Dhandhukia

Hamm‐Alvarez

et al. 2016

Journal of Controlled Release

132

104

View full text Add to dashboard Cite

Elastin-like polypeptides (ELPs) constitute a genetically engineered class of ‘protein polymers’ derived from human tropoelastin. They exhibit a reversible phase separation whereby samples remain soluble below a transition temperature (Tt) but form amorphous coacervates above Tt. Their phase behavior has many possible applications in purification, sensing, activation, and nanoassembly. As humanized polypeptides, they are non-immunogenic, substrates for proteolytic biodegradation, and can be decorated with pharmacologically active peptides, proteins, and small molecules. Recombinant synthesis additionally allows precise control over ELP architecture and molecular weight, resulting in protein polymers with uniform physicochemical properties suited to the design of multifunctional biologics. As such, ELPs have been employed for various uses including as anti-cancer agents, ocular drug delivery vehicles, and protein trafficking modulators. This review aims to offer the reader a catalogue of ELPs, their various applications, and potential for commercialization across a broad spectrum of fields.

show abstract

“…Other biomaterials used to create nanoparticles by plasmid DNA condensation include poly-arginine and elastin-like polypeptide [120, 121]. Specifically, Dash et al developed a hydrogel that contains hollow elastin-based spheres carrying plasmid endothelial nitric oxide synthase (NOS3) and IL-10, which showed approximately 3-fold increase in perfusion ratio of ischemic to non-ischemic limb and in blood vessel surface density in mouse hindlimb ischemia.…”

Section: Pro-angiogenesismentioning

confidence: 99%

Gene delivery nanoparticles to modulate angiogenesis

Kim

Mirando

Popel

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Angiogenesis is naturally balanced by many pro- and anti-angiogenic factors while an imbalance of these factors leads to aberrant angiogenesis, which is closely associated with many diseases. Gene therapy has become a promising strategy for the treatment of such a disordered state through the introduction of exogenous nucleic acids that express or silence the target agents, thereby engineering neovascularization in both directions. Numerous non-viral gene delivery nanoparticles have been investigated towards this goal, but their clinical translation has been hampered by issues associated with safety, delivery efficiency, and therapeutic effect. This review summarizes key factors targeted for therapeutic angiogenesis and anti-angiogenesis gene therapy, non-viral nanoparticle-mediated approaches to gene delivery, and recent gene therapy applications in pre-clinical and clinical trials for ischemia, tissue regeneration, cancer, and wet age-related macular degeneration. Enhanced nanoparticle design strategies are also proposed to further improve the efficacy of gene delivery nanoparticles to modulate angiogenesis.

show abstract

An injectable elastin-based gene delivery platform for dose-dependent modulation of angiogenesis and inflammation for critical limb ischemia

Cited by 53 publications

References 47 publications

Recent Advances in Nanomaterials for Gene Delivery—A Review

Recent Advances in Nanomaterials for Gene Delivery—A Review

Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines

Gene delivery nanoparticles to modulate angiogenesis

Contact Info

Product

Resources

About